

1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ZICHE1

In re Application of:	)	Conf. No.: 5690
	)	
Marina ZICHE et al	)	Art Unit: 1653
	)	
Appln. No.: 09/756,185	)	Examiner: R. Mitra
	)	
Filed: January 9, 2001	)	Washington, D.C.
	)	
For: COMPOUND B AS ANGIOGENIC	)	January 25, 2005
AGENT IN COMBINATION WITH	)	
HUMAN GROWTH FACTORS	)	

COMMUNICATION

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Randolph Building, Mail Stop Amendments  
401 Dulany Street  
Alexandria, VA 22314

Sir:

We are in receipt of a communication from the Manager of the Publishing Division in the Office of Patent Publication, entitled "Priority Acknowledgement", in response to the paper filed November 29, 2004, entitled "Request for Priority" that forwarded a certified copy of the European patent application from which this application claims priority.

The communication from the PTO is a form letter with four boxes. Box two was checked, i.e., "Applicant's claim for priority, based on papers filed in parent Application Number

In re of Appln. No. 09/719,748

PCT/EP99/04605 submitted under 35 U.S.C. 119, is  
acknowledged."


It is pointed out that the above-identified  
application is a continuation of PCT/EP99/04605 and not a  
national stage. Therefore, it is believed that Box One should  
have been checked, i.e.: "Receipt is acknowledged of priority  
papers submitted under 35 U.S.C. 119. The papers have been  
placed of record in the file."


Please correct the record in this regard.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

  
Roger L. Browdy  
Registration No. 25,618

  
Allen Yum  
Reg. No. 37,971

RLB:rd  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\S\Ser1\Zichel\PTO\Communication.doc